SARS-CoV-2 Omicron XBB.1 variant outbreak in a defined cohort: an epidemiological investigation incorporating longitudinal assessment of humoral response

Int J Infect Dis. 2024 Nov:148:107240. doi: 10.1016/j.ijid.2024.107240. Epub 2024 Sep 11.

Abstract

Background: We describe an epidemiological investigation of a SARS-CoV-2-XBB.1 outbreak among healthcare workers (HCWs) returning from a 5-days educational tour abroad.

Methods: We prospectively followed participants for symptoms and sampled blood for neutralization assays of four SARS-CoV-2 variants (wild type, XBB, EG.5.1, and BA.2.86) at 1, 3, and 6 months after their return. When available, samples from the 3 months preceding the outbreak were also tested. We compared geometric mean titers (GMT) of neutralizing antibodies of infected versus uninfected HCWs and febrile versus afebrile infected HCWs.

Results: Nineteen (10%) of 181 HCWs were infected, all had mild COVID-19, 90% (17/19) had symptoms, and 16% (3/19) reported fever. Infected individuals tended to have lower pre-exposure XBB-neutralizing antibody titers (GMT of 32 versus 107 ID50, P = 0.248). Neutralization against XBB and newer subvariants peaked at 3 months and was higher among infected individuals (GMT 702 versus 156 [P < 0.001], 558 versus 163 [P = 0.001], and 558 vs. 182 [P = 0.002], ID50 for XBB, EG.5.1., and BA.2.86, respectively). By six months, these differences were no longer observed. Fever was positively associated with XBB neutralization (GMT 3474 versus 485, ID50 P = 0.005).

Conclusions: Recently infected individuals are protected from reinfection with newer subvariants. However, protection is likely short lived.

Keywords: COVID-19; Healthcare workers; Infection control; Virus neutralization.

MeSH terms

  • Adult
  • Antibodies, Neutralizing* / blood
  • Antibodies, Viral* / blood
  • COVID-19* / epidemiology
  • COVID-19* / immunology
  • Disease Outbreaks
  • Female
  • Health Personnel*
  • Humans
  • Immunity, Humoral
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Neutralization Tests
  • Prospective Studies
  • SARS-CoV-2* / genetics
  • SARS-CoV-2* / immunology

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral

Supplementary concepts

  • SARS-CoV-2 variants